Agency orders withdrawal of cannabis-derived medicines sold on an online platform without authorization
Anvisa () banned on Monday (April 13, 2026) the marketing and advertising of products sold through the platform. The determination is contained in Resolution 1,494/2026, published in the Official Gazette of the Union. The products do not have registration or health authorization. Here is it (PDF – 98 KB).
The agency identified the sale of cannabis-derived medicines without regulatory authorization through the platform. According to Anvisa, the sale of medicines without health registration violates health surveillance standards. The manufacturer of the products was not identified.
Cannabidiol (CBD) is a chemical compound extracted from the plant Cannabis sativa –known as marijuana.
Recalled products
Anvisa also ordered the recall of batch 2515799 of the drug Enalapril Maleate 20 mg, manufactured by 1Farma Indústria Farmacêutica Ltda. Dark spots were detected on the tablets, caused by failure to disperse components during production.
According to the agency, the analyzes did not indicate a risk to the health of patients.
Seizure of aesthetic product
The Rejuviskin Plus product, from Ensofill Aesthetic Products Ltdwas also the target of sanitary measures. Anvisa ordered the seizure and prohibited the use, sale, manufacture, import and dissemination of the item.
According to the agency, the product does not have health registration and the company does not have authorization to manufacture medicines.
This text was originally published by , on April 16, 2026. The content is free for republication, citing the source, it was adapted to the standard of Poder360 and received additional information.
